A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels

Koo Wilson*, John Marriott, Stephen Fuller, Loretto Lacey, David Gillen

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Background: Coronary heart disease (CHD) is a public health priority in the UK. The National Service Framework (NSF) has set standards for the prevention, diagnosis and treatment of CHD, which include the use of cholesterol-lowering agents aimed at achieving targets of blood total cholesterol (TC) < 5.0 mmol/L and low density lipoprotein-cholesterol (LDL-C) < 3.0 mmol/L. In order to achieve these targets cost effectively, prescribers need to make an informed choice from the range of statins available. Aim: To estimate the average and relative cost effectiveness of atorvastatin, fluvastatin, pravastatin and simvastatin in achieving the NSF LDL-C and TC targets. Design: Model-based economic evaluation. Methods: An economic model was constructed to estimate the number of patients achieving the NSF targets for LDL-C and TC at each dose of statin, and to calculate the average drug cost and incremental drug cost per patient achieving the target levels. The population baseline LDL-C and TC, and drug efficacy and drug costs were taken from previously published data. Estimates of the distribution of patients receiving each dose of statin were derived from the UK national DIN-LINK database. Results: The estimated annual drug cost per 1000 patients treated with atorvastatin was £289 000, with simvastatin £315 000, with pravastatin £333 000 and with fluvastatin £167 000. The percentages of patients achieving target are 74.4%, 46.4%, 28.4% and 13.2% for atorvastatin, simvastatin, pravastatin and fluvastatin, respectively. Incremental drug cost per extra patient treated to LDL-C and TC targets compared with fluvastafin were £198 and £226 for atorvastatin, £443 and £567 for simvastatin and £1089 and £2298 for pravastatin, using 2002 drug costs. Conclusions: As a result of its superior efficacy, atorvastatin generates a favourable cost-effectiveness profile as measured by drug cost per patient treated to LDL-C and TC targets. For a given drug budget, more patients would achieve NSF LDL-C and TC targets with atorvastatin than with any of the other statins examined.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalPharmacoEconomics
Volume21
Issue numberSuppl.1
DOIs
Publication statusPublished - Dec 2003

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Drug Costs
Cost-Benefit Analysis
fluvastatin
LDL Cholesterol
Cholesterol
Pravastatin
Simvastatin
Coronary Disease
Economic Models
Health Priorities
Budgets
Pharmaceutical Preparations
Atorvastatin Calcium
Public Health
Databases
Costs and Cost Analysis

Keywords

  • atorvastatin
  • therapeutic use
  • cost effectiveness
  • fluvastatin
  • HMG CoA reductase inhibitors
  • hypercholesterolaemia
  • treatment
  • pharmacoeconomics
  • pravastatin
  • simvastatin

Cite this

Wilson, Koo ; Marriott, John ; Fuller, Stephen ; Lacey, Loretto ; Gillen, David. / A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels. In: PharmacoEconomics . 2003 ; Vol. 21, No. Suppl.1. pp. 1-11.
@article{59df39b1951b4e2da13c3eccb95665d5,
title = "A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels",
abstract = "Background: Coronary heart disease (CHD) is a public health priority in the UK. The National Service Framework (NSF) has set standards for the prevention, diagnosis and treatment of CHD, which include the use of cholesterol-lowering agents aimed at achieving targets of blood total cholesterol (TC) < 5.0 mmol/L and low density lipoprotein-cholesterol (LDL-C) < 3.0 mmol/L. In order to achieve these targets cost effectively, prescribers need to make an informed choice from the range of statins available. Aim: To estimate the average and relative cost effectiveness of atorvastatin, fluvastatin, pravastatin and simvastatin in achieving the NSF LDL-C and TC targets. Design: Model-based economic evaluation. Methods: An economic model was constructed to estimate the number of patients achieving the NSF targets for LDL-C and TC at each dose of statin, and to calculate the average drug cost and incremental drug cost per patient achieving the target levels. The population baseline LDL-C and TC, and drug efficacy and drug costs were taken from previously published data. Estimates of the distribution of patients receiving each dose of statin were derived from the UK national DIN-LINK database. Results: The estimated annual drug cost per 1000 patients treated with atorvastatin was £289 000, with simvastatin £315 000, with pravastatin £333 000 and with fluvastatin £167 000. The percentages of patients achieving target are 74.4{\%}, 46.4{\%}, 28.4{\%} and 13.2{\%} for atorvastatin, simvastatin, pravastatin and fluvastatin, respectively. Incremental drug cost per extra patient treated to LDL-C and TC targets compared with fluvastafin were £198 and £226 for atorvastatin, £443 and £567 for simvastatin and £1089 and £2298 for pravastatin, using 2002 drug costs. Conclusions: As a result of its superior efficacy, atorvastatin generates a favourable cost-effectiveness profile as measured by drug cost per patient treated to LDL-C and TC targets. For a given drug budget, more patients would achieve NSF LDL-C and TC targets with atorvastatin than with any of the other statins examined.",
keywords = "atorvastatin, therapeutic use, cost effectiveness, fluvastatin, HMG CoA reductase inhibitors, hypercholesterolaemia, treatment, pharmacoeconomics, pravastatin, simvastatin",
author = "Koo Wilson and John Marriott and Stephen Fuller and Loretto Lacey and David Gillen",
year = "2003",
month = "12",
doi = "10.2165/00019053-200321001-00001",
language = "English",
volume = "21",
pages = "1--11",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "Suppl.1",

}

A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels. / Wilson, Koo; Marriott, John; Fuller, Stephen; Lacey, Loretto; Gillen, David.

In: PharmacoEconomics , Vol. 21, No. Suppl.1, 12.2003, p. 1-11.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels

AU - Wilson, Koo

AU - Marriott, John

AU - Fuller, Stephen

AU - Lacey, Loretto

AU - Gillen, David

PY - 2003/12

Y1 - 2003/12

N2 - Background: Coronary heart disease (CHD) is a public health priority in the UK. The National Service Framework (NSF) has set standards for the prevention, diagnosis and treatment of CHD, which include the use of cholesterol-lowering agents aimed at achieving targets of blood total cholesterol (TC) < 5.0 mmol/L and low density lipoprotein-cholesterol (LDL-C) < 3.0 mmol/L. In order to achieve these targets cost effectively, prescribers need to make an informed choice from the range of statins available. Aim: To estimate the average and relative cost effectiveness of atorvastatin, fluvastatin, pravastatin and simvastatin in achieving the NSF LDL-C and TC targets. Design: Model-based economic evaluation. Methods: An economic model was constructed to estimate the number of patients achieving the NSF targets for LDL-C and TC at each dose of statin, and to calculate the average drug cost and incremental drug cost per patient achieving the target levels. The population baseline LDL-C and TC, and drug efficacy and drug costs were taken from previously published data. Estimates of the distribution of patients receiving each dose of statin were derived from the UK national DIN-LINK database. Results: The estimated annual drug cost per 1000 patients treated with atorvastatin was £289 000, with simvastatin £315 000, with pravastatin £333 000 and with fluvastatin £167 000. The percentages of patients achieving target are 74.4%, 46.4%, 28.4% and 13.2% for atorvastatin, simvastatin, pravastatin and fluvastatin, respectively. Incremental drug cost per extra patient treated to LDL-C and TC targets compared with fluvastafin were £198 and £226 for atorvastatin, £443 and £567 for simvastatin and £1089 and £2298 for pravastatin, using 2002 drug costs. Conclusions: As a result of its superior efficacy, atorvastatin generates a favourable cost-effectiveness profile as measured by drug cost per patient treated to LDL-C and TC targets. For a given drug budget, more patients would achieve NSF LDL-C and TC targets with atorvastatin than with any of the other statins examined.

AB - Background: Coronary heart disease (CHD) is a public health priority in the UK. The National Service Framework (NSF) has set standards for the prevention, diagnosis and treatment of CHD, which include the use of cholesterol-lowering agents aimed at achieving targets of blood total cholesterol (TC) < 5.0 mmol/L and low density lipoprotein-cholesterol (LDL-C) < 3.0 mmol/L. In order to achieve these targets cost effectively, prescribers need to make an informed choice from the range of statins available. Aim: To estimate the average and relative cost effectiveness of atorvastatin, fluvastatin, pravastatin and simvastatin in achieving the NSF LDL-C and TC targets. Design: Model-based economic evaluation. Methods: An economic model was constructed to estimate the number of patients achieving the NSF targets for LDL-C and TC at each dose of statin, and to calculate the average drug cost and incremental drug cost per patient achieving the target levels. The population baseline LDL-C and TC, and drug efficacy and drug costs were taken from previously published data. Estimates of the distribution of patients receiving each dose of statin were derived from the UK national DIN-LINK database. Results: The estimated annual drug cost per 1000 patients treated with atorvastatin was £289 000, with simvastatin £315 000, with pravastatin £333 000 and with fluvastatin £167 000. The percentages of patients achieving target are 74.4%, 46.4%, 28.4% and 13.2% for atorvastatin, simvastatin, pravastatin and fluvastatin, respectively. Incremental drug cost per extra patient treated to LDL-C and TC targets compared with fluvastafin were £198 and £226 for atorvastatin, £443 and £567 for simvastatin and £1089 and £2298 for pravastatin, using 2002 drug costs. Conclusions: As a result of its superior efficacy, atorvastatin generates a favourable cost-effectiveness profile as measured by drug cost per patient treated to LDL-C and TC targets. For a given drug budget, more patients would achieve NSF LDL-C and TC targets with atorvastatin than with any of the other statins examined.

KW - atorvastatin

KW - therapeutic use

KW - cost effectiveness

KW - fluvastatin

KW - HMG CoA reductase inhibitors

KW - hypercholesterolaemia

KW - treatment

KW - pharmacoeconomics

KW - pravastatin

KW - simvastatin

UR - http://www.scopus.com/inward/record.url?scp=0344022558&partnerID=8YFLogxK

UR - http://link.springer.com/article/10.2165%2F00019053-200321001-00001

U2 - 10.2165/00019053-200321001-00001

DO - 10.2165/00019053-200321001-00001

M3 - Article

C2 - 12648030

VL - 21

SP - 1

EP - 11

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - Suppl.1

ER -